Results 251 to 260 of about 350,705 (311)
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang +16 more
wiley +1 more source
Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration. [PDF]
Shahannaz DC, Sugiura T.
europepmc +1 more source
A Mussel‐Inspired Bioadhesive Patch to Selectively Kill Glioblastoma Cells
An innovative mussel‐inspired bioadhesive patch has been developed for post‐surgical glioblastoma treatment. The patch, which adheres strongly in biological environments, releases a localized treatment. This treatment, acting via reactive oxygen species, shows specific toxicity to glioblastoma cells.
Jose Bolaños‐Cardet +5 more
wiley +1 more source
PANoptosis and mitochondrial regulatory mechanisms in cerebral ischemia-reperfusion injury. [PDF]
Li L +11 more
europepmc +1 more source
Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis
ABSTRACT Osteoporosis, characterized by progressive bone loss and increased fracture risk, is a growing concern as the population ages. Current treatments, though advanced, remain limited, underscoring the necessity for novel therapeutic targets. Recent studies have shown that the immune system plays a key role in osteoporosis, with osteoclasts driving
Chaowen Bai +15 more
wiley +1 more source
Research progress on mitochondria in bone defect repair: mechanisms and therapeutic implications. [PDF]
Hu Z, Chen G, Long Z.
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source

